Osimertinib reactivated immune-related colitis after treatment with anti-PD1 antibody for non-small cell lung cancer

Takenaka, Tomoyoshi; Yamazaki, Koji; Miura, Naoko; Harada, Naohiko; Takeo, Sadanori
December 2017
Investigational New Drugs;Dec2017, Vol. 35 Issue 6, p848
Academic Journal
We reported a case of relapsing immune-related colitis (initially caused by nivolumab) following osimertinib therapy for lung adenocarcinoma. A 45-year-old female who had never smoked was diagnosed with adenocarcinoma of the lung and underwent surgical resection. Four years after surgical resection, she was diagnosed with recurrent disease and was eventually treated with nivolumab as third-line therapy. One month after the completion of nivolumab therapy, the patient reported abdominal pain and frequent diarrhea. We diagnosed immune-related colitis and started oral prednisolone. However, the steroid therapy was ineffective, so the patient was administered infliximab and an increased dose of prednisolone. Her symptoms subsequently resolved, and her mucosal lesions improved. Six months after the last administration of nivolumab, osimertinib was initiated as fourth-line therapy, but 3 days later, the patient developed blood in the stool and frequent diarrhea. Osimertinib treatment was discontinued, given the possibility that it had reactivated the patient's immune-related colitis. We subsequently re-administered oral prednisolone (2 mg/kg/day), and the colitis resolved within a few weeks.


Related Articles

  • Infliximab/prednisone.  // Reactions Weekly;2/13/2016, Vol. 1588 Issue 1, p148 

    The article reports development of Kaposi's sarcoma by a 21-year-old man following treatment with prednisone for his IgA nephropathy and infliximab for Crohn's disease.

  • Methylprednisolone/prednisone.  // Reactions Weekly;8/14/2010, Issue 1314, p30 

    The article describes the case of a 72-year-old man who acquired invasive Aspergillus colitis while undergoing treatment with methylprednisolone and prednisone.

  • Thyroid Cancer and T Lymphoblastic Leukemia in Crohn Disease: A Case Report and Literature Review. Ja Min Byun; Sun Kyung Baek; Hwi-Joong Yoon; Si-Young Kim; Chi Hoon Maeng; Tae Sung Park; Hyo-Jong Kim; Yun Young Choi; Yu Jin Um // Laboratory Medicine;Spring2015, Vol. 46 Issue 2, p140 

    The effectiveness of the tumor necrosis--α (TNF-α) blockade has changed the treatment of several chronic inflammatory diseases, including inflammatory bowel disease; however, this treatment also has disadvantages. The use of immunosuppressants in combination with infliximab has been...

  • Successful Use of Infliximab in the Treatment of Corticosteroid Dependent Collagenous Colitis. Pola, Suresh; Fahmy, Marianne; Evans, Elisabeth; Tipps, Ann; Sandborn, William J // American Journal of Gastroenterology;May2013, Vol. 108 Issue 5, p857 

    A letter to the editor related to the use of infliximab in the treatment of corticosteroid dependent collagenous colitis is presented.

  • Ulcerative colitis is not a rare complication of Takayasu arteritis. Watanabe, Ryu; Ishii, Tomonori; Nakamura, Kyohei; Shirai, Tsuyoshi; Fujii, Hiroshi; Saito, Shinichiro; Harigae, Hideo // Modern Rheumatology;Mar2014, Vol. 24 Issue 2, p372 

    No abstract available.

  • Always a Suspect: CMV in Ulcerative Colitis. Kommareddy, Shirisha; Chun, Carlene; Rogers, William; Triadafilopoulos, George // Digestive Diseases & Sciences;Jul2013, Vol. 58 Issue 7, p1838 

    No abstract available.

  • Infliximab/tocilizumab.  // Reactions Weekly;12/12/2015, Vol. 1581 Issue 1, p187 

    A case study by A. Mekinian and colleagues published in the journal "Circulation" concerning a one patient developed lung cancer following therapy with infliximab and one patient developed breast cancer following therapy with tocilizumab is presented.

  • Researchers aiming to suppress therapy resistance in brain cancer.  // Medical Device Daily;7/8/2013, Vol. 17 Issue 129, p2 

    This article reports that neurooncologist professor Michael Platten and fellow researchers from the German Cancer Research Center and the Department of Neurooncology of Heidelberg University Hospital are working to find other methods of treating gliomas more effectively. Radiotherapy in...

  • Eli Lilly: Alimta to challenge the dominance of Taxotere.  // PharmaWatch: Cancer;October 2004, Vol. 3 Issue 10, p8 

    This article reports that recently approved Alimta may find cost the major hurdle to widespread uptake. The FDA approval of Lilly's Alimta for second line treatment of advanced NSCLC means that it will be in direct competition with Sanofi -Aventis' Taxotere and, given its equal efficacy but...

  • P3–093EFFICACY AND TOXICITY OF CRIZOTINIB FOR PATIENTS WITH ALK-POSITIVE ADVANCED NSCLC. Asao, T.; Honma, Y.; Suina, K.; Muraki, K.; Shukuya, T.; Ohashi, R.; Koyama, R.; Shimada, N.; Sakuraba, S.; Takahashi, K. // Annals of Oncology;Nov2013 Supplement 9, Vol. 24, pix94 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics